Embodiments of the disclosure concern engineered T cell receptors that are specific for the survivin tumor antigen but do not have “on-target off tumor” toxicity. In particular embodiments, particular alpha and beta chains are utilized in engineered T cell receptors for cell therapy that have effective anti-tumor activity but lack fratricidal effects. Methods, compositions, and kits are provided herein.

Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.

The present invention provides methods for culturing primary cells and tissues from a subject in the presence of the subject's own serum, ascites or pleural effusion fluid. Methods of treating cancer, and screening for the effectiveness or toxicity of drugs are also provided herein.

A diagnostic test is described using Aspergillus flavus fungal cultures, EBV or their combination to induce leukemic cell surface markers in mononuclear cells of former or current leukemia patients. Unlike aflotoxin, which indiscriminately induces leukemic transformation, the compositions used were specific to leukemia-predisposed patients, but not other cancers or normal controls. The test identifies survivors of ALL and can detect propensity for development of leukemia in susceptible individuals. An ELISA technique using the described fungal products or EBV and combination can detect individuals with history of leukemia and not controls. These findings have implications for the etiology of leukemias and lymphomas and use for mass screening, detection of susceptible individuals to leukemia and potential vaccination.

Provided are a cancer cell-trapping metal filter which has a high opening ratio, a cancer cell-trapping metal filter sheet, a cancer cell-trapping device using the cancer cell-trapping filter, and manufacturing methods therefor.

According to a cancer cell-trapping metal filter 1, openings of connected through-holes 12 that are formed in a metal sheet 11 have a wave shape, and thus it is possible to extract a CTC from other components by utilizing a hole diameter on a short-side side of the openings, and it is possible to make the connected through-holes be closer to each other due to the wave shape while maintaining a CTC trapping ability. Accordingly, it is possible to further improve the opening ratio in the cancer cell-trapping metal filter 1.

A particle filtering device which shortens the separation time of particles and increases the separation efficiency are provided. The particle filtering device comprises: a filtration membrane which separates a particle by filtering a sample; a first body connected to an inlet side of the filtration membrane, which supplies the sample to the inlet side of the filtration membrane; and a second body connected to an outlet side of the filtration membrane, which accommodates a permeate whose particle is separated through the filtration membrane, wherein the particle filtering device has a structure in which the permeate is accommodated in advance between the second body and the outlet side of the filtration membrane.

Compositions and methods for inhibiting, treating, and/or preventing a B-cell neoplasm are provided.

The present disclosure provides a modified cell of leukemic origin comprising a downregulated CD47 pathway. Methods for using the modified cells in treating cancer alone, or in combination with CD47 blockade are also provided. Also provided are compositions comprising a modified cell of leukemic origin, pharmaceutical compositions and formulations thereof, and methods of producing the modified cells.

Methods and systems for isolating platelet-associated nucleated target cells, e.g., such as circulating epithelial cells, circulating tumor cells (CTCs), circulating endothelial cells (CECs), circulating stem cells (CSCs), neutrophils, and macrophages, from sample fluids, e.g., biological fluids, such as blood, bone marrow, plural effusions, and ascites fluid, are described. The methods include obtaining a cell capture chamber including a plurality of binding moieties bound to one or more walls of the chamber, wherein the binding moieties specifically bind to platelets; flowing the sample fluid through the cell capture chamber under conditions that allow the binding moieties to bind to any platelet-associated nucleated target cells in the sample to form complexes; and separating and collecting platelet-associated nucleated target cells from the complexes.

Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, acute leukemia cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable.